Taysha gene therapies announces positive clinical data across adult and pediatric patients from low dose cohort in ongoing reveal phase 1/2 trials evaluating tsha-102 in rett syndrome

Durable improvements across consistent clinical domains in both adult and pediatric patients, including motor skills, communication/socialization, autonomic function, seizures, and an encouraging safety profile seen across adult (up to 52 weeks) and pediatric (up to 22 weeks) patients with different genetic mutation severity
TSHA Ratings Summary
TSHA Quant Ranking